Suppr超能文献

在接受在线血液透析滤过治疗的国际突发事件透析队列中,改善患者预后的最佳对流体积。

Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration.

作者信息

Canaud Bernard, Barbieri Carlo, Marcelli Daniele, Bellocchio Francesco, Bowry Sudhir, Mari Flavio, Amato Claudia, Gatti Emanuele

机构信息

Montpellier University I, UFR Medicine, Montpellier, France.

Fresenius Medical Care, Bad Homburg, Germany.

出版信息

Kidney Int. 2015 Nov;88(5):1108-16. doi: 10.1038/ki.2015.139. Epub 2015 May 6.

Abstract

Online hemodiafiltration (OL-HDF), the most efficient renal replacement therapy, enables enhanced removal of small and large uremic toxins by combining diffusive and convective solute transport. Randomized controlled trials on prevalent chronic kidney disease (CKD) patients showed improved patient survival with high-volume OL-HDF, underlining the effect of convection volume (CV). This retrospective international study was conducted in a large cohort of incident CKD patients to determine the CV threshold and range associated with survival advantage. Data were extracted from a cohort of adult CKD patients treated by post-dilution OL-HDF over a 101-month period. In total, 2293 patients with a minimum of 2 years of follow-up were analyzed using advanced statistical tools, including cubic spline analyses for determination of the CV range over which a survival increase was observed. The relative survival rate of OL-HDF patients, adjusted for age, gender, comorbidities, vascular access, albumin, C-reactive protein, and dialysis dose, was found to increase at about 55 l/week of CV and to stay increased up to about 75 l/week. Similar analysis of pre-dialysis β2-microglobin (marker of middle-molecule uremic toxins) concentrations found a nearly linear decrease in marker concentration as CV increased from 40 to 75 l/week. Analysis of log C-reactive protein levels showed a decrease over the same CV range. Thus, a convection dose target based on convection volume should be considered and needs to be confirmed by prospective trials as a new determinant of dialysis adequacy.

摘要

在线血液透析滤过(OL-HDF)是最有效的肾脏替代治疗方法,它通过结合扩散和对流溶质转运,能够增强对大小尿毒症毒素的清除。针对慢性肾脏病(CKD)患者的随机对照试验表明,大容量OL-HDF可提高患者生存率,突出了对流体积(CV)的作用。这项回顾性国际研究在一大群初诊CKD患者中进行,以确定与生存优势相关的CV阈值和范围。数据来自一组在101个月期间接受后稀释OL-HDF治疗的成年CKD患者。总共对2293例至少随访2年的患者进行了分析,使用了先进的统计工具,包括三次样条分析,以确定观察到生存率增加的CV范围。在调整了年龄、性别、合并症、血管通路、白蛋白、C反应蛋白和透析剂量后,发现OL-HDF患者的相对生存率在CV约为55升/周时开始增加,并在高达约75升/周时保持上升。对透析前β2-微球蛋白(中分子尿毒症毒素标志物)浓度进行的类似分析发现,随着CV从40升/周增加到75升/周,标志物浓度几乎呈线性下降。对log C反应蛋白水平的分析显示在相同的CV范围内也有所下降。因此,应考虑基于对流体积的对流剂量目标,并且需要通过前瞻性试验确认为透析充分性的新决定因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c05b/4653588/9eaa36b3267c/ki2015139f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验